Breaking Finance News

Vetr Inc. issued a report on EXACT Sciences Corporation (NASDAQ:EXAS), boosting its stock price target to $36.37 today

Only yesterday EXACT Sciences Corporation (NASDAQ:EXAS) traded 1.92% higher at $36.02. EXAS’s 50-day average is $37.62 and its two hundred day average is $28.82. With the last stock price close up 31.00% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.05% over the same time. 1,183,339 shares of EXAS traded hands, down from an average trading volume of 2,971,130

EXACT Sciences Corporation (NASDAQ:EXAS) had its stock price target increased to $36.37 by Vetr Inc. in an issued report announced 7/06/2017. The bumped up target suggests a potential upside of 0.01% from the company's most recent close.

On 06/28/2017, Vetr Inc. reported on EXACT Sciences Corporation (NASDAQ:EXAS) increased the target price from $0.00 to $37.46 that suggested an upside of 0.10%.

Recent Performance Chart

EXACT Sciences Corporation (NASDAQ:EXAS)

EXACT Sciences Corporation has 52 week low of $13.05 and a 52 week high of $42.18 and has a market cap of $0.

Also covering EXACT Sciences Corporation's target, a total of 10 equity analysts have released a research note on the company. The average stock price target is $8.55 with 5 analysts rating the company a strong buy, one analyst rating the company a buy, 7 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and lastly zero equity analysts rating the company a sell.

Brief Synopsis About EXACT Sciences Corporation (NASDAQ:EXAS)

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *